This evidence summary discusses 4 randomised controlled trials (RCTs) in adults who were obese or overweight (BMI 27 kg/m2 or above) with a variety of weight-related comorbidities including dyslipidaemia, hypertension, type 2 diabetes and obstructive sleep apnoea (NICE)
Diabetes News
Tag: liraglutide
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
In a population with type 2 diabetes at high cardiovascular risk, there were numerically fewer events of acute pancreatitis among liraglutide-treated patients (regardless of previous history of pancreatitis) compared with the placebo group (Diabetes Care)
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes
Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes (The Lancet)
Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial
A 12-week treatment with liraglutide or sitagliptin only resulted in a brief and modest increase of plasma pancreatic enzyme concentrations in patients with type 2 diabetes. Apart from a minimal sitagliptin-induced increase in intraduodenal fluid secretion, pancreatic exocrine function was unaffected (Diabetes Care)
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial
Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed (European Journal of Heart Failure)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo (NEJM)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Liraglutide was safe, well tolerated, and led to histological resolution of non-alcoholic steatohepatitis, warranting extensive, longer-term studies (The Lancet)
Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
Adding liraglutide to multiple daily insulin injections in people with type 2 diabetes improves glycaemic control without an increased risk of hypoglycaemia, reduces body weight, and enables patients to lower their insulin doses (BMJ)
Victoza® (liraglutide) provides significantly greater HbA1c reduction than lixisenatide in new clinical trial
Findings from a head-to-head trial comparing Victoza® (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs -1.21% for lixisenatide in adults with type 2 diabetes (Novo Nordisk)
Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes
Based on a risk/benefit assessment of the overall dataset from the two ADJUNCT trials, Novo Nordisk does currently not intend to submit an application to expand the label of Victoza® for use in type 1 diabetes (Novo Nordisk)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide (3.0 mg) daily, compared with placebo, resulted in weight loss over 56 weeks. Further studies are needed to evaluate longer-term efficacy and safety (JAMA)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control (NEJM)
United States first country to launch Saxenda
Novo Nordisk announce that Saxenda® (liraglutide 3 mg) is now available in the United States (US). Saxenda® is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management, approved in the US, EU and Canada
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
Lixisenatide and liraglutide improved glycemic control in optimized insulin glargine-treated T2D albeit with contrasting mechanisms of action and differing safety profiles (Diabetes Care)
The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes
Older age and non-metformin use were associated with more significant GISE leading to discontinuation of liraglutide treatment. The reasons for these findings are unclear and warrant further investigation (Diabetes Research and Clinical Practice)
Saxenda® approved in Europe for the treatment of obesity
Novo Nordisk announce that the European Commission has granted marketing authorisation for Saxenda® (liraglutide 3mg) for the treatment of obesity. The authorisation covers all 28 European Union (EU) member states.
Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity
Novo Nordisk announce that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity
This site complies with the 